Terms and definitions related to ReNU Syndrome (RNU4-2), genetics and therapies.
This glossary contains the most important terms for understanding ReNU Syndrome (RNU4-2). Each definition is prepared by the Scientific Committee of Sindrome ReNU Italia APS (Dr. Claudia Gravaghi PhD) and includes the scientific reference source.
Italian fiscal mechanism allowing taxpayers to allocate 5 per thousand of their income tax to a non-profit organisation at no additional cost. To allocate your 5×1000 to Sindrome ReNU Italia APS, enter tax code 98020680157 in the "Social promotion associations" box of your Italian tax return. This is not an additional donation: you decide where a share of taxes already owed to the State goes.
Educational-behavioural approach based on applied behaviour analysis principles. Helps children learn new skills (communication, independence, learning) and reduce behaviours that hinder daily life. Highly personalised, uses positive reinforcement and continuous progress monitoring. One of the most evidence-based interventions for children with neurodevelopmental disabilities.
System of tools and strategies that augments or replaces verbal language for people with severe communication difficulties. Includes: picture/symbol communication boards (PECS), electronic communicators (VOCA), tablet apps, coded gestures (e.g. KWS – Keyword Sign). Indicated for non-verbal or limited-communication children, including many with ReNU Syndrome.
The set of cognitive, behavioural and adaptive characteristics observable in a patient with a given genetic variant. In ReNU Syndrome, the behavioural phenotype includes: moderate-to-severe intellectual disability, autistic traits (ASD), generally cheerful and sociable temperament, love of music, water and routines, reduced pain threshold, repetitive behaviours.
Ciaccio et al., AJMG B 2026 (PMID 41681065)
Partial or complete underdevelopment of the corpus callosum, the brain structure that connects the two hemispheres. A frequent neuroradiological marker in ReNU Syndrome, often associated with reduced white matter volume.
Visual impairment of cerebral (not ocular) origin: the problem is not in the eye but in the brain's ability to interpret visual information. Frequent in ReNU Syndrome patients, often associated with optic nerve hypoplasia, strabismus and nystagmus.
Chromosomal location of the RNU4-2 gene in the human genome: chromosome 12, long arm (q), region 2, band 4, sub-band 31. This notation describes the physical location on the standard chromosomal map (GRCh38).
Unique identifier assigned to a patient participating in clinical research. The CRID allows safe linking of a patient's data across different studies without revealing patient identity. For children with ReNU Syndrome, creating a CRID at thecrid.org before participating in any clinical study is recommended.
thecrid.org
Child and Adolescent Neuropsychiatry Unit: hospital department specialising in the diagnosis and treatment of neurological, psychiatric and neurodevelopmental disorders in developmental age. UONPIA at Policlinico di Milano (Fondazione IRCCS) is one of the Italian reference centres for ReNU Syndrome.
A genetic mutation present in the patient but not inherited from biological parents: it arises for the first time in the patient's germline or in early embryonic development. Almost all known pathogenic RNU4-2 variants are de novo: recurrence risk in the same family is very low (<1%).
Hollingsworth et al., Nature 2024
Type of seizure characteristic of infancy (typical onset 3–12 months). Manifests as brief symmetrical limb contractions. In ReNU Syndrome, epilepsy is present in 65–70% of patients and may include infantile spasms, focal seizures, tonic-clonic seizures and febrile convulsions.
Ciaccio et al., AJMG B 2026
Identification of a disease in its early stages, before symptoms become severe or damage accumulates. For ReNU Syndrome, early diagnosis (within the first year of life) is crucial because it allows timely initiation of support therapies and avoids years of diagnostic uncertainty. The standard pathway often requires first a WES (frequently negative) then WGS, with average delays of 2–5 years.
Quality evaluation framework used by Google (and indirectly by AI engines) to assess YMYL (Your Money or Your Life) sites, including health and medical sites. For Sindrome ReNU Italia APS: Experience = stories of 24 Italian families; Expertise = Dr. Claudia Gravaghi PhD and Scientific Committee; Authoritativeness = citations in Nature, AJMG; Trustworthiness = public APS statute, verifiable contacts.
Google Search Quality Evaluator Guidelines 2024
Condition characterised by significant limitations in intellectual functioning (IQ < 70) and adaptive behaviour (conceptual, social, practical skills), with onset in the developmental period. Present in almost all ReNU Syndrome patients, moderate-to-severe in 90%+ of cases.
Hollingsworth et al., Nature 2024
Italian law guaranteeing protections, benefits and services to people with disabilities and their families. For a child with ReNU Syndrome it includes: support teacher, work leave for caregiver (3 days/month or 2 hours/day), VAT reductions on assistive devices, healthcare ticket exemptions, disabled parking permit. Recognition is through the INPS medical commission.
Testamentary disposition by which the testator leaves part of their estate (money, property, securities) to a Social Promotion Association (APS). In Italy, legacies to APS organisations are exempt from inheritance tax. The legacy can be: universal (entire estate or a share) or particular (a specific asset). For information: donazioni@sindromerenu.it.
Head circumference below the 3rd percentile for age and sex. A recurrent clinical sign in ReNU Syndrome patients, particularly in those with severe phenotype. May be congenital or develop postnatally.
Reduced muscle tone (passive resistance to movement). Frequent in ReNU Syndrome infants and children, manifesting as muscle "flaccidity", motor developmental delay, difficulty maintaining upright posture. May also affect oro-facial muscles, contributing to feeding and speech difficulties.
Online biomedical database managed by Johns Hopkins University cataloguing human genetic diseases and associated genes. ReNU Syndrome is catalogued in OMIM under number 620849. OMIM is a primary source for researchers and physicians studying rare genetic diseases.
https://www.omim.org/entry/620849
Proportion of individuals in a population with a given condition at a given time. ReNU Syndrome has an estimated prevalence of approximately 1 in 35,000 live births, classifying it as ultra-rare (EU threshold: fewer than 5 per 10,000). In Italy, approximately 16 diagnosed cases are known, but the real number is likely much higher due to diagnostic deficit.
Hollingsworth et al., Nature 2024
Structured database collecting clinical, genetic and anamnestic data from patients with a specific disease. For rare diseases like ReNU Syndrome, the patient registry is essential for: collecting sufficient data for clinical studies, identifying common phenotypic patterns, facilitating trial recruitment. Sindrome ReNU Italia APS is collaborating on the National ReNU Patient Registry with UONPIA Policlinico di Milano.
Unique identifier assigned by the National Library of Medicine (NIH/NLM) to each scientific article indexed in PubMed. Key PMIDs for ReNU Syndrome publications: 39169177 (Hollingsworth et al., Nature 2024), 42419151, 41681065 (Ciaccio et al., AJMG B 2026), 41951959.
Gene encoding snRNA U4, located on chromosome 12 (12q24.31). It is a non-coding gene (produces a functional RNA, not a protein). Known pathogenic variants concentrate in only 13 critical nucleotides of the gene sequence. The disease caused by variants of this gene was named "ReNU Syndrome" (or RNU4-2 Syndrome) by the international scientific community in 2024.
Hollingsworth et al., Nature 2024 (PMID 39169177)
Biological process whereby introns (non-coding sequences) are removed from pre-mRNA and exons (coding sequences) are joined to form mature mRNA. Carried out by the spliceosome. Pathogenic RNU4-2 variants impair this process, leading to aberrant intron inclusion or exon skipping, producing abnormal proteins or reduced gene expression.
Small nuclear RNA encoded by the RNU4-2 gene, an essential component of the U4/U6.U5 tri-snRNP splicing complex. Pathogenic variants in RNU4-2 impair spliceosome function and cause ReNU Syndrome.
Hollingsworth et al., Nature 2024 (PMID 39169177)
RNA-protein macromolecular complex that catalyses the removal of introns from pre-mRNA (splicing). Composed of 5 main snRNAs (U1, U2, U4, U5, U6) and hundreds of proteins. Spliceosome dysfunction causes aberrant transcripts and neurodevelopmental pathology.
Italian legal form of Third Sector entity (Legislative Decree 117/2017). Characterised by: prevalence of activities in the general interest, volunteer members operating non-profit, public statute, registration in the RUNTS (National Third Sector Register). APS organisations benefit from tax advantages. Sindrome ReNU Italia APS is registered with tax code 98020680157.
Dilation of the lateral cerebral ventricles, detectable by brain MRI. It is one of the most frequent neuroradiological markers in ReNU Syndrome, often associated with callosal hypoplasia and white matter reduction.
Sequencing of the entire human genome (≈ 3 billion base pairs). Detects variants in all genomic regions, including the deep intronic regions where RNU4-2 pathogenic variants reside. It is the only reliable diagnostic test for ReNU Syndrome. Typical turnaround: 2–4 weeks.
Targeted sequencing of only the exome, i.e. protein-coding exons (≈ 2% of the genome). Not suitable for diagnosing ReNU Syndrome, as RNU4-2 pathogenic variants reside in a deep intronic region that WES does not analyse. Many ReNU patients initially received a negative WES, resulting in years of diagnostic delay.
